HEALTH2 weeks ago
Ocaliva for NASH receives negative feedback from FDA advisors
The FDA External Review Panel stated that obeticholic acid (Ocaliva) does not have a favorable risk-benefit ratio for the treatment of non-alcoholic steatohepatitis (NASH) with precirrhotic...
